Di Yu, Xu Hai-Yan, Ye Jun-Jie, Li Meng-Da
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
Department of Ophthalmology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
Int J Ophthalmol. 2021 Apr 18;14(4):574-581. doi: 10.18240/ijo.2021.04.15. eCollection 2021.
To investigate the clinical manifestations, diagnostic approaches, treatments, and outcomes of intraocular lymphoma.
In this retrospective study, 16 patients (28 eyes) with intraocular lymphoma were recruited in the Department of Ophthalmology, Peking Union Medical College Hospital, from 2004 to 2019. All patients underwent comprehensive ophthalmic examinations. Vitreous specimens of 13 patients were sent for cytopathology examination and other adjunctive diagnostic procedures. Three patients were diagnosed with intraocular lymphoma according to analysis of the histopathological results of systemic lymphoma by one clinician. Twenty-three eyes were treated with intravitreal administration of methotrexate, 4 eyes could not receive ocular treatment due to life-threatening lymphoma, and 1 eye did not require ocular treatment because the fundus lesions regressed after systematic chemotherapy.
In 28 eyes, 25 eyes were diagnosed with vitreoretinal lymphoma, and 3 eyes were diagnosed with ciliary body lymphoma, all of which were non-Hodgkin diffuse large B cell lymphomas. The final visual acuity improved in 15 eyes (54%), remained unchanged in 5 eyes (18%), and decreased in 8 eyes (29%). Anterior segment inflammation disappeared or reduced in 8 and 5 eyes, respectively; and 15 eyes had no anterior segment reaction. Twenty eyes had mild vitreous opacity, 1 eye had mild vitritis, and 7 eyes had pars plana vitrectomy combined with silicone oil tamponade. Fundus lesions disappeared in 9 eyes and were relieved in 5 eyes; 4 eyes showed no changes, and the remaining 10 eyes' fundus were normal.
The clinical manifestations of intraocular lymphoma are diverse, and the misdiagnosis rate is high. Cytopathological analysis of vitreous is one of the gold standards for the diagnosis. Immunohistochemistry, gene rearrangement and flow cytometric immunophenotypic analysis can improve the diagnostic rate. Ocular chemotherapy or radiotherapy regimens may preserve visual acuity, and a multidisciplinary team can provide individualized treatment for the patients.
探讨眼内淋巴瘤的临床表现、诊断方法、治疗及预后。
本回顾性研究纳入了2004年至2019年期间在北京协和医院眼科就诊的16例(28只眼)眼内淋巴瘤患者。所有患者均接受了全面的眼科检查。13例患者的玻璃体标本送检进行细胞病理学检查及其他辅助诊断程序。3例患者根据一名临床医生对系统性淋巴瘤组织病理学结果的分析被诊断为眼内淋巴瘤。23只眼接受了玻璃体内注射甲氨蝶呤治疗,4只眼因危及生命的淋巴瘤无法接受眼部治疗,1只眼因系统性化疗后眼底病变消退而无需眼部治疗。
28只眼中,25只眼被诊断为玻璃体视网膜淋巴瘤,3只眼被诊断为睫状体淋巴瘤,均为非霍奇金弥漫性大B细胞淋巴瘤。15只眼(54%)最终视力提高,5只眼(18%)视力不变,8只眼(29%)视力下降。眼前段炎症分别在8只眼和5只眼中消失或减轻;15只眼无眼前段反应。20只眼有轻度玻璃体混浊,1只眼有轻度玻璃体炎,7只眼行玻璃体切割联合硅油填充术。9只眼眼底病变消失,5只眼缓解;4只眼无变化,其余10只眼眼底正常。
眼内淋巴瘤临床表现多样,误诊率高。玻璃体细胞病理学分析是诊断的金标准之一。免疫组织化学、基因重排和流式细胞术免疫表型分析可提高诊断率。眼部化疗或放疗方案可保留视力,多学科团队可为患者提供个体化治疗。